415 related articles for article (PubMed ID: 22633086)
21. Imaging of NETs with PET radiopharmaceuticals.
Ambrosini V; Tomassetti P; Franchi R; Fanti S
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):16-23. PubMed ID: 20168283
[TBL] [Abstract][Full Text] [Related]
22. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
23. Imaging neuroendocrine tumours with radionuclide techniques.
Gnanasegaran G; O'Doherty MJ
Minerva Endocrinol; 2008 Jun; 33(2):105-26. PubMed ID: 18425057
[TBL] [Abstract][Full Text] [Related]
24. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
25. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
26. Update on nuclear medicine imaging of neuroendocrine tumors.
Goldsmith SJ
Future Oncol; 2009 Feb; 5(1):75-84. PubMed ID: 19243300
[TBL] [Abstract][Full Text] [Related]
27. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA
Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743
[TBL] [Abstract][Full Text] [Related]
28. Divergent role of (68)Ga-labeled somatostatin analogs in the workup of patients with NETs: AIIMS experience.
Naswa N; Bal CS
Recent Results Cancer Res; 2013; 194():321-51. PubMed ID: 22918767
[TBL] [Abstract][Full Text] [Related]
29. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
Panagiotidis E; Bomanji J
PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
[TBL] [Abstract][Full Text] [Related]
30. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C
AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
[TBL] [Abstract][Full Text] [Related]
31. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
32. Diagnostics of neuroendocrine tumours.
Hodolic M; Fettich J; Banti E; Chondrogiannis S; Al-Nahhas A; Rubello D
In Vivo; 2010; 24(5):771-4. PubMed ID: 20952747
[TBL] [Abstract][Full Text] [Related]
33. Functional imaging of neuroendocrine tumours with PET.
Mottaghy FM; Reske SN
Pituitary; 2006; 9(3):237-42. PubMed ID: 17036194
[TBL] [Abstract][Full Text] [Related]
34. Nuclear Medicine Imaging of Neuroendocrine Tumors.
Brabander T; Kwekkeboom DJ; Feelders RA; Brouwers AH; Teunissen JJ
Front Horm Res; 2015; 44():73-87. PubMed ID: 26303705
[TBL] [Abstract][Full Text] [Related]
35. Guideline for PET/CT imaging of neuroendocrine neoplasms with
Bozkurt MF; Virgolini I; Balogova S; Beheshti M; Rubello D; Decristoforo C; Ambrosini V; Kjaer A; Delgado-Bolton R; Kunikowska J; Oyen WJG; Chiti A; Giammarile F; Sundin A; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1588-1601. PubMed ID: 28547177
[TBL] [Abstract][Full Text] [Related]
36. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
37. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
[TBL] [Abstract][Full Text] [Related]
38. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
[TBL] [Abstract][Full Text] [Related]
39. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.
Sathekge M; Maes A; D'Asseler Y; Vorster M; Van de Wiele C
Nucl Med Commun; 2012 Jun; 33(6):581-90. PubMed ID: 22422098
[TBL] [Abstract][Full Text] [Related]
40. Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
Cuccurullo V; Di Stasio GD; Mansi L
Curr Radiopharm; 2019; 12(2):98-106. PubMed ID: 30727940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
